Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R B Rothman

Showing results (181-190 of 262) with videos related to

Pageof 27
Sort By:
Journal of Substance Abuse Treatment|April 1, 2000
An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependenceR B Rothman, D A Gorelick, S J Heishman, et al.
Peptides|November 1, 1992
Probing the opioid receptor complex with (+)-trans-SUPERFIT. II. Evidence that mu ligands are noncompetitive inhibitors of the delta cx opioid peptide binding siteR B Rothman, A Mahboubi, V Bykov, et al.
NIDA Research Monograph|January 1, 1986
Upregulation of the mu-noncompetitive delta binding site by chronic morphine administration: effect of preincubating membranes in 400 nM sodium chlorideJ A Danks, F C Tortella, V Bykov, et al.
Neuropharmacology|May 1, 1991
(+)-cis-3-methylfentanyl and its analogs bind pseudoirreversibly to the mu opioid binding site: evidence for pseudoallosteric modulationH Xu, C H Kim, Y C Zhu, et al.
NIDA Research Monograph|January 1, 1991
[3H]1,3-Di(2-tolyl)guanidine labels two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel blockers and sigma ligandsR B Rothman, A Mahboubi, A A Reid, et al.
Molecular Pharmacology|February 1, 1991
Labeling by [3H]1,3-di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel antagonists and pseudoallosteric modulation by sigma ligandsR B Rothman, A Reid, A Mahboubi, et al.
Neuropeptides|October 1, 1988
A brief study of the selectivity of norbinaltorphimine, (-)-cyclofoxy, and (+)-cyclofoxy among opioid receptor subtypes in vitroR B Rothman, V Bykov, A Reid, et al.
European Journal of Pharmacology|January 24, 1989
Chronic administration of morphine and naltrexone up-regulate mu-opioid binding sites labeled by [3H][D-Ala2,MePhe4,Gly-ol5]enkephalin: further evidence for two mu-binding sitesR B Rothman, V Bykov, J B Long, et al.
Synapse (New York, N.Y.)|November 9, 2000
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotoninR B Rothman, M H Baumann, C M Dersch, et al.
Neurochemical Research|September 1, 1994
Dihydrocodeinone-hydrazone, dihydrocodeinone-oxime, naloxone-3-OMe-oxime, and clocinnamox fail to irreversibly inhibit opioid kappa receptor bindingQ Ni, H Xu, J S Partilla, et al.
Pageof 27

Showing results (181-190 of 262) with videos related to

Sort By:
Pageof 27
Journal of Substance Abuse Treatment|April 1, 2000
An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependenceR B Rothman, D A Gorelick, S J Heishman, et al.
Peptides|November 1, 1992
Probing the opioid receptor complex with (+)-trans-SUPERFIT. II. Evidence that mu ligands are noncompetitive inhibitors of the delta cx opioid peptide binding siteR B Rothman, A Mahboubi, V Bykov, et al.
NIDA Research Monograph|January 1, 1986
Upregulation of the mu-noncompetitive delta binding site by chronic morphine administration: effect of preincubating membranes in 400 nM sodium chlorideJ A Danks, F C Tortella, V Bykov, et al.
Neuropharmacology|May 1, 1991
(+)-cis-3-methylfentanyl and its analogs bind pseudoirreversibly to the mu opioid binding site: evidence for pseudoallosteric modulationH Xu, C H Kim, Y C Zhu, et al.
NIDA Research Monograph|January 1, 1991
[3H]1,3-Di(2-tolyl)guanidine labels two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel blockers and sigma ligandsR B Rothman, A Mahboubi, A A Reid, et al.
Molecular Pharmacology|February 1, 1991
Labeling by [3H]1,3-di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel antagonists and pseudoallosteric modulation by sigma ligandsR B Rothman, A Reid, A Mahboubi, et al.
Neuropeptides|October 1, 1988
A brief study of the selectivity of norbinaltorphimine, (-)-cyclofoxy, and (+)-cyclofoxy among opioid receptor subtypes in vitroR B Rothman, V Bykov, A Reid, et al.
European Journal of Pharmacology|January 24, 1989
Chronic administration of morphine and naltrexone up-regulate mu-opioid binding sites labeled by [3H][D-Ala2,MePhe4,Gly-ol5]enkephalin: further evidence for two mu-binding sitesR B Rothman, V Bykov, J B Long, et al.
Synapse (New York, N.Y.)|November 9, 2000
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotoninR B Rothman, M H Baumann, C M Dersch, et al.
Neurochemical Research|September 1, 1994
Dihydrocodeinone-hydrazone, dihydrocodeinone-oxime, naloxone-3-OMe-oxime, and clocinnamox fail to irreversibly inhibit opioid kappa receptor bindingQ Ni, H Xu, J S Partilla, et al.
Pageof 27